Concepedia

Paul Sims

PS

11

Publications

1.3K

Citations

11

H-Index

1995

Active since

Affiliations

Dynavax Technologies (United States)(Current)

Dana-Farber Cancer Institute

University of Vienna

Paul Sims is an author at Dynavax Technologies (United States) specializing in medicine, autoimmunity, and hematology.

Top concepts

Publications per year

1995–2016

11

Publications

11

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 385 citations

Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies

Laura Simmons, Dorothea Reilly, Laura Klimowski et al. · Journal of Immunological Methods · 2002 · 289 citations

, , +10

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity

Jonathan W. Friedberg, Helen Kim, Mary McCauley et al. · Blood · 2004 · 151 citations · Full text

Blunted Thrombopoietin Response to Interferon Alfa-Induced Thrombocytopenia During Treatment for Hepatitis C

Markus Peck‐Radosavljevic, Martina Wichlas, Johann Pidlich et al. · Hepatology · 1998 · 100 citations · Full text

, , +23

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Jonathan W. Friedberg, Jennifer L. Kelly, Donna Neuberg et al. · British Journal of Haematology · 2009 · 79 citations · Full text

, , +19

Rows per page

1–5 of 11